Nectar Lifesciences sells core API business for Rs 1290 crore; stock crashes 20%
Nectar Lifesciences, a pharmaceutical company, sold its core API and formulation business, along with its Menthol Assets, to Ceph Lifesciences for Rs 1290 crore. This deal is significant as it accounted for 98.33% of the company's total revenue in fiscal year 2025. The proceeds will be used for debt repayment, rewarding shareholders, and investing in new projects.